Irritable bowel syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:07:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0.1 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Irritable bowel syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Saccharomyces boulardii CNCM I-745 to treat symptoms in adults with non-constipated Irritable Bowel Syndrome https://clinicaltrials.eu/trial/study-of-saccharomyces-boulardii-cncm-i-745-to-treat-symptoms-in-adults-with-non-constipated-irritable-bowel-syndrome/ Wed, 29 Apr 2026 15:07:10 +0000 https://clinicaltrials.eu/trial/study-of-saccharomyces-boulardii-cncm-i-745-to-treat-symptoms-in-adults-with-non-constipated-irritable-bowel-syndrome/ This study focuses on Irritable Bowel Syndrome (IBS), specifically the non-constipated type, which is a disorder affecting the digestive system that can cause stomach pain, bloating, and changes in bowel habits. The study will test a treatment called Saccharomyces boulardii CNCM I-745, which is a type of beneficial yeast, comparing it with a placebo. Another medication called loperamide may be used during the study to help manage symptoms.

The purpose of this research is to determine if Saccharomyces boulardii CNCM I-745 can improve overall IBS symptoms when taken over an 8-week period. The treatment will be given in the form of hard capsules that are taken by mouth. The study will measure how the treatment affects various aspects of the condition, including stomach pain, bloating, and overall quality of life.

During the study, participants will take either the treatment or placebo for 12 weeks. The researchers will monitor any changes in symptoms throughout this period and continue observations for some time after the treatment ends. They will also keep track of any side effects that might occur during the study period. The study is designed so that neither the participants nor the doctors know who is receiving the actual treatment or the placebo until the study is complete.

]]> Study on the Effectiveness of E. coli DSM 17252 for Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-e-coli-dsm-17252-for-patients-with-diarrhea-predominant-irritable-bowel-syndrome-ibs-d/ Wed, 29 Apr 2026 15:00:38 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-e-coli-dsm-17252-for-patients-with-diarrhea-predominant-irritable-bowel-syndrome-ibs-d/ This clinical trial is focused on studying a condition known as Irritable Bowel Syndrome, specifically the type that mainly causes diarrhea, referred to as IBS-D. The treatment being tested is called Symbioflor®2, which contains living bacteria known as Escherichia coli DSM 17252. The trial will compare the effects of this treatment to a placebo, which looks and feels the same as the treatment but does not contain the active bacteria.

The purpose of the study is to see how effective Symbioflor®2 is in reducing the frequency and severity of symptoms in patients with IBS-D. It will also assess the safety and how well patients tolerate the treatment. Participants in the study will take the treatment or placebo orally, meaning they will swallow it, over a period of 26 weeks. During this time, researchers will monitor changes in symptoms and any side effects experienced by the participants.

Throughout the study, participants will be asked to report on their symptoms, such as abdominal pain and stool consistency, using simple scales. This will help researchers determine if the treatment is making a significant difference compared to the placebo. The study aims to provide valuable information on whether Symbioflor®2 can be a helpful treatment option for those suffering from IBS-D.

]]> Study on the Effects of GSL-01-001 for Patients with Irritable Bowel Syndrome (IBS) Type D https://clinicaltrials.eu/trial/study-on-the-effects-of-gsl-01-001-for-patients-with-irritable-bowel-syndrome-ibs-type-d/ Wed, 29 Apr 2026 14:58:53 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-gsl-01-001-for-patients-with-irritable-bowel-syndrome-ibs-type-d/ This clinical trial is focused on studying Irritable Bowel Syndrome with diarrhea (IBS-D), a condition that causes symptoms like abdominal pain, cramping, nausea, bloating, and diarrhea. The treatment being tested is a medication called GSL-01-001, which is taken orally. The purpose of the study is to evaluate how effective and safe this medication is in managing the symptoms associated with IBS-D.

The study will last for a total of 14 weeks, starting with a 2-week screening period followed by 12 weeks of treatment. During this time, participants will take the medication GSL-01-001 and will be monitored for any changes in their symptoms, as well as any side effects they might experience. The study aims to see if the medication can help reduce symptoms like abdominal pain, bloating, and diarrhea, and improve overall comfort and quality of life for those with IBS-D.

Participants will be asked to report on their symptoms regularly, and the study will track changes in things like abdominal pain and stool consistency. The safety of the medication will also be closely monitored throughout the study. This trial is an important step in understanding whether GSL-01-001 can be a helpful treatment option for people living with IBS-D.

]]> Study on the Effectiveness and Safety of Myrrh, Coffee Charcoal, and Chamomile Extract for Patients with Diarrhea-Dominant or Mixed-Type Irritable Bowel Syndrome https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-myrrh-coffee-charcoal-and-chamomile-extract-for-patients-with-diarrhea-dominant-or-mixed-type-irritable-bowel-syndrome/ Wed, 29 Apr 2026 14:58:46 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-myrrh-coffee-charcoal-and-chamomile-extract-for-patients-with-diarrhea-dominant-or-mixed-type-irritable-bowel-syndrome/ This clinical trial is focused on studying the effects of a treatment called MYRRHINIL-INTEST® on patients with two types of irritable bowel syndrome: diarrhea-dominant irritable bowel syndrome (IBS-D) and mixed-type irritable bowel syndrome (IBS-M). MYRRHINIL-INTEST® is a coated tablet that contains natural ingredients such as myrrh, coffee charcoal, and a dry extract from chamomile flower. The purpose of the study is to evaluate how effective and safe this treatment is compared to a placebo, which looks like the treatment but does not contain the active ingredients.

Participants in the study will take either the MYRRHINIL-INTEST® tablets or the placebo for a period of up to eight weeks. During this time, they will be asked to keep a diary to record their symptoms, such as abdominal pain, stool consistency, and frequency of bowel movements. The study will involve several visits to the study center, where participants will have their symptoms assessed and their overall gut health evaluated. The study aims to see if the treatment can help reduce symptoms like abdominal pain and improve the quality of life for those with IBS-D and IBS-M.

Throughout the study, participants’ health will be monitored closely, including checking vital signs like blood pressure and pulse, and conducting blood tests. The study will also track any side effects that may occur. The goal is to determine if MYRRHINIL-INTEST® is a safe and effective option for managing symptoms of irritable bowel syndrome.

]]> Study on the Effectiveness and Safety of Myrrh, Coffee Charcoal, and Chamomile Extract for Patients with Diarrhea-Predominant Irritable Bowel Syndrome https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-myrrh-coffee-charcoal-and-chamomile-extract-for-patients-with-diarrhea-predominant-irritable-bowel-syndrome/ Wed, 29 Apr 2026 14:58:41 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-myrrh-coffee-charcoal-and-chamomile-extract-for-patients-with-diarrhea-predominant-irritable-bowel-syndrome/ This clinical trial is focused on studying the effects of a treatment called MYRRHINIL-INTEST® on patients with diarrhea-predominant irritable bowel syndrome (IBS-D). This condition is a type of irritable bowel syndrome where diarrhea is the main symptom. The treatment being tested is a coated tablet that contains natural ingredients such as myrrh, coffee charcoal, and a dry extract from chamomile flower. These ingredients are known for their potential to help with digestive issues.

The purpose of the study is to evaluate how effective and safe MYRRHINIL-INTEST® is compared to a placebo, which looks like the treatment but does not contain any active ingredients. Participants in the study will take either the treatment or the placebo for a period of up to eight weeks. During this time, they will be asked to keep a diary to record their symptoms, such as stool frequency and consistency, and any feelings of incomplete bowel movements. The study will also assess the overall quality of life and any changes in the severity of IBS-D symptoms.

Throughout the study, participants will have regular visits to the study center to monitor their progress and ensure their safety. These visits will include assessments of vital signs like blood pressure and pulse, as well as checks on clinical chemistry and hematology, which are tests that look at blood and other bodily fluids. The study aims to provide valuable information on whether MYRRHINIL-INTEST® can be a helpful treatment option for those suffering from IBS-D.

]]> Study Comparing Ebastine and Mebeverine for Treating Irritable Bowel Syndrome in Adults https://clinicaltrials.eu/trial/study-comparing-ebastine-and-mebeverine-for-treating-irritable-bowel-syndrome-in-adults/ Wed, 29 Apr 2026 14:24:41 +0000 https://clinicaltrials.eu/trial/study-comparing-ebastine-and-mebeverine-for-treating-irritable-bowel-syndrome-in-adults/ This clinical trial is focused on studying the effects of two medications, Ebastine and Mebeverine, in treating Irritable Bowel Syndrome (IBS). IBS is a common condition that affects the large intestine, causing symptoms like abdominal pain, bloating, and changes in bowel habits. The purpose of this study is to compare how well these two medications work in relieving the symptoms of IBS and improving the quality of life for those affected.

Participants in the study will be randomly assigned to receive either Ebastine, Mebeverine, or a placebo. Ebastine is typically used to treat allergies, while Mebeverine is used to relieve stomach cramps and spasms. The study will last for a period of 12 weeks, during which participants will take the assigned medication orally. Throughout the study, participants will be monitored to assess changes in their symptoms, such as abdominal pain and overall relief of IBS symptoms.

The trial aims to determine which medication is more effective in managing IBS symptoms and to evaluate the impact on participants’ quality of life. By the end of the study, researchers hope to gather valuable information that could lead to better treatment options for individuals suffering from IBS. Participants will be asked to report their symptoms regularly, and their progress will be closely followed by the research team.

]]> Study of Fecal Microbiota Transplantation in Capsule Form Compared to Placebo for Patients with Severe Irritable Bowel Syndrome https://clinicaltrials.eu/trial/study-on-fecal-microbiota-transplantation-capsules-vs-placebo-for-patients-with-severe-irritable-bowel-syndrome/ Wed, 29 Apr 2026 14:22:45 +0000 https://clinicaltrials.eu/trial/study-on-fecal-microbiota-transplantation-capsules-vs-placebo-for-patients-with-severe-irritable-bowel-syndrome/ This clinical trial focuses on treating severe Irritable Bowel Syndrome (IBS), a condition that affects the digestive system causing symptoms like abdominal pain, bloating, and changes in bowel habits. The study tests a treatment called Fecal Microbiota Transplantation (FMT), which involves transferring beneficial gut bacteria from healthy donors to patients. The treatment is given in the form of oral capsules containing frozen fecal microbiota.

The purpose of this research is to determine if these oral capsules containing fecal microbiota are effective in reducing the severity of IBS symptoms compared to placebo. The treatment involves taking oral capsules that contain either the fecal microbiota transplant or placebo. The maximum daily dose is 32 grams, and the treatment period lasts for one day.

The study will monitor patients for 24 weeks to assess changes in their IBS symptoms and overall quality of life. The research team will evaluate how the treatment affects the balance of bacteria in the digestive system and track any improvements in IBS-related symptoms. This is a double-blind study, which means neither the patients nor the doctors know who receives the actual treatment or placebo during the study period.

]]>